- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for subjects with mHSPC.
Critère d'inclusion
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)